Acquisition of Gracell completed AstraZeneca has agreed to acquire Gracell Biotechnologies, a company developing cell therapies for cancer and autoimmune diseases, for up to $1.2bn. The deal will add GC012F, a dual-targeting CAR-T therapy for multiple myeloma, to AstraZeneca’s portfolio of cell therapies. Gracell Biotechnologies will operate as a wholly owned subsidiary of AstraZeneca, with…